Spero Therapeutics to Report Third Quarter 2024 Financial Results and Provide Business Update on Thursday, November 14, 2024

11/7/24 4:05:00 PM ET

Biotechnology: Pharmaceutical Preparations

Health Care

Get the next $SPRO alert in real time by email

CAMBRIDGE, Mass., Nov. 07, 2024 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (NASDAQ:SPRO), a multi-asset clinical-stage biopharmaceutical company, focused on identifying and developing novel treatments for rare diseases and multi-drug resistant (MDR) bacterial infections, today announced that it will report its third quarter 2024 financial results and provide an update on its business on Thursday, November 14, after the market close. The Company does not intend to host a conference call.

About Spero Therapeutics

Spero Therapeutics, headquartered in Cambridge, Massachusetts, is a multi-asset, clinical-stage biopharmaceutical company focused on identifying and developing novel treatments for rare diseases and multi-drug resistant (MDR) bacterial infections. For more information - www.sperotherapeutics.com

Investor Relations Contact:

Shai Biran, PhD

Spero Therapeutics

[email protected]

Media Inquiries:

[email protected]

Get the next $SPRO alert in real time by email

Date	Price Target	Rating	Analyst
9/23/2022	$2.00 → $8.00	In-line → Outperform	Evercore ISI
10/1/2021		Outperform → Perform	Oppenheimer

Spero Therapeutics to Report Third Quarter 2024 Financial Results and Provide Business Update on Thursday, November 14, 2024

Chat with this insight

Recent Analyst Ratings for $SPRO

$SPRO Large Ownership Changes

This live feed shows all institutional transactions in real time.

SEC Form SC 13G filed by Spero Therapeutics Inc.

SEC Form SC 13G/A filed by Spero Therapeutics Inc. (Amendment)

SEC Form SC 13G/A filed by Spero Therapeutics Inc. (Amendment)

$SPRO Leadership Updates

Live Leadership Updates

$SPRO Insider Trading

Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

Spero Therapeutics Appoints Esther Rajavelu as Chief Financial Officer and Chief Business Officer

Sensorium Therapeutics Appoints Veteran Life Sciences Executive Mr. David Southwell to its Board of Directors

Spero Therapeutics Appoints Sath Shukla as President & Chief Executive Officer

Director Mahadevia Ankit sold $7,981 worth of shares (5,912 units at $1.35), decreasing direct ownership by 0.77% to 759,085 units (SEC Form 4)

Chief Operating Officer Keutzer Timothy sold $2,988 worth of shares (2,213 units at $1.35), decreasing direct ownership by 0.41% to 531,837 units (SEC Form 4)

CEO & President Shukla Sath sold $3,722 worth of shares (2,757 units at $1.35), decreasing direct ownership by 0.24% to 1,140,809 units (SEC Form 4)

$SPRO Press Releases

Fastest customizable press release news feed in the world

Spero Therapeutics to Report Third Quarter 2024 Financial Results and Provide Business Update on Thursday, November 14, 2024

Spero Therapeutics Announces SPR720 Phase 2a Interim Results and Provides a Business Update

Spero Therapeutics Announces Presentation of SPR719 (Active Moiety of SPR720) In Vitro Data Demonstrating Low Propensity for the Development of Resistance at IDWeek 2024

$SPRO Financials

Live finance-specific insights

$SPRO Analyst Ratings

Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

$SPRO SEC Filings

Spero Therapeutics to Report Third Quarter 2024 Financial Results and Provide Business Update on Thursday, November 14, 2024

Spero Therapeutics Announces Second Quarter 2024 Operating Results and Provides a Business Update

Spero Therapeutics to Report Second Quarter 2024 Financial Results and Provide Business Update on Monday, August 5, 2024

Spero Therapeutics upgraded by Evercore ISI with a new price target

Spero Therapeutics downgraded by Oppenheimer

HC Wainwright & Co. reiterated coverage on Spero Therapeutics

Spero Therapeutics Inc. filed SEC Form 8-K: Costs Associated with Exit or Disposal Activities, Regulation FD Disclosure

SEC Form 8-K filed by Spero Therapeutics Inc.

SEC Form S-8 filed by Spero Therapeutics Inc.

$SPRO Market Insights

Live Market Insights

HC Wainwright & Co. Reiterates Buy on Spero Therapeutics, Maintains $7 Price Target

Spero Therapeutics Q1 2024 GAAP EPS $(0.24) Misses $(0.04) Estimate, Sales $9.267M Miss $21.533M Estimate

Cantor Fitzgerald Reiterates Overweight on Spero Therapeutics

Recent Analyst Ratings for
$SPRO

$SPRO
Large Ownership Changes

$SPRO
Leadership Updates

$SPRO
Insider Trading

$SPRO
Press Releases

$SPRO
Financials

$SPRO
Analyst Ratings

$SPRO
SEC Filings

$SPRO
Market Insights